HUYABIO International
HUYABIO is a San Diego company that licenses Chinese-discovered medicines for the rest of the world; its lead is tucidinostat, the oral HDAC inhibitor approved in China and Japan for T-cell lymphoma, which it took into a phase 3 trial in melanoma with a checkpoint inhibitor.
Overview
HUYABIO International, based in San Diego, in-licenses drug candidates from Chinese companies and develops them outside China. Its lead compound tucidinostat (HBI-8000, chidamide), a class I HDAC inhibitor approved in China for peripheral T-cell lymphoma and breast cancer and in Japan for lymphoma, was tested with nivolumab in the phase 3 trial registered on ClinicalTrials.gov under HUYABIO as lead sponsor.
Scorecard
All companies- approved products +6
- modalities +2
- regions +2
- registry trials +30
Similar pages
not linked directly; found by shared links- CompanyImmuneOncia Therapeutics
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyGeorgiamune
Shares Pivotal (registrational) trial, Clinical trial, Melanoma and the tag ctgov-sponsor.
- CompanyHiberCell
Shares Pivotal (registrational) trial, Clinical trial, Melanoma and the tag ctgov-sponsor.
- CompanyIdera Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Melanoma and the tag ctgov-sponsor.
- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.